# Special Issue

# Pharmacogenomics: Challenges and Future

## Message from the Guest Editors

Over the past years, the growth of pharmacogenomics (PGx) within the medical community has contributed to improving the practice of precision medicine. The genetic make-up influences interindividual variability in drugs response in terms of dosing, drug efficacy/toxicity, hypersensitivity reactions, drug resistance, and clinical outcome. The discovery of PGx biomarkers may lead to tailored prescription, with a major impact on healthcare costs. Until now, FDA recommendations are provided for over 200 drugs in several therapeutic areas, especially for cancer. However, PGx implementation is still limited, and several barriers need to be overcome. For this Special Issue. contributions from both experts and beginners in the PGx field are invited. We welcome reviews and original research articles covering many aspects of PGx, from the discovery of new PGx biomarkers to methodological strategies to increase PGx knowledge and implementation, including validation of PGx biomarkers for clinical translation. Moreover, studies on ethical, legal, and economic aspects and on the role of epigenetic and non-genetic factors are also welcome.

#### **Guest Editors**

Dr. Mariamena Arbitrio

Dr. Maria Teresa Di Martino

Dr. Francesca Scionti

## Deadline for manuscript submissions

closed (5 September 2023)

G C A T T A C G G C A T

## Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/74105

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/ genes



## G C A T T A C G G C A T

# Genes

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 5.5 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the Genes team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider Genes for your next genetics paper?

## Editor-in-Chief

## Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

#### **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

